Smith & Nephew (LON:SN) Downgraded to “Sector perform” Rating by Royal Bank Of Canada

Smith & Nephew (LON:SN) was downgraded by equities researchers at Royal Bank Of Canada to a “sector perform” rating in a report released on Thursday,Digital Look reports. They currently have a GBX 1,350 target price on the stock. Royal Bank Of Canada’s price objective would indicate a potential upside of 16.48% from the company’s current price.

Other equities research analysts have also recently issued reports about the company. Berenberg Bank reiterated a “hold” rating and set a GBX 13 target price on shares of Smith & Nephew in a research note on Friday, May 1st. UBS Group reissued a “neutral” rating and issued a GBX 1,300 price objective on shares of Smith & Nephew in a report on Tuesday. Two equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of GBX 1,185.86.

Smith & Nephew Trading Up 1.0%

Shares of LON:SN opened at GBX 1,159 on Thursday. The company has a current ratio of 2.57, a quick ratio of 0.84 and a debt-to-equity ratio of 62.90. The company’s fifty day moving average is GBX 1,236.09 and its two-hundred day moving average is GBX 1,258.20. The company has a market cap of £12.71 billion, a PE ratio of 41.73, a PEG ratio of 0.46 and a beta of 0.74.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.